Herantis Pharma PLC · OMXHEX:HRTIS

Herantis Pharma — Investor Presentation (September 2021)

24 slides from Herantis Pharma's investor presentation, September 2021

  1. Slide 1: Herantis Corporate Presentation September 2021

    Herantis Corporate Presentation September 2021 1

  2. Slide 2: Disclaimer

    Disclaimer By accepting to receive this presentation from Herantis Pharma Plc (the "Company"), you agree to be bound by the following conditions. This presentation and any oral communication in connection with it (the "Information") are strictly confidential and are being provided to you solely for

  3. Slide 3: Company Overview

    Company Overview • Headquartered in Helsinki, listed on Nasdaq First North Finland and Sweden • Founded 2008, IPO 2014 (Finland) 2019 (Sweden), €63m raised to date, €15m in 2020 • Research focus is assets that modify human pathology as result of protein dysregulation • Disease focus is on Parkinson’

  4. Slide 4: Pipeline Fully Focused On Neurodegenerative Diseases

    Pipeline Fully Focused On Neurodegenerative Diseases rh rh CDNF = Cerebral Dopamine Neurotrophic Factor 4

  5. Slide 5: Two Stand Alone Molecules, Same MoA, Same Target … Individual Approaches

    Two Stand Alone Molecules, Same MoA, Same Target … Individual Approaches rhCDNF xCDNF (HER096) Protein, clinical stage Phase I data on Target Disease - Chemical, pre-clinical stage. molecule, intranasal spray Parkinsons subcutaneous administration administration Target Organ - Brain Target Pathology

  6. Slide 6: rhCDNF and xCDNF Data Continues To Build

    rhCDNF and xCDNF Data Continues To Build MoA & Target Engagement Disease Biomarkers Market Proteostasis Blood Brain Biomarkers Favorable target engagement Barrier respond safety profile, validated, penetration significantly to and no proteostasis is high for rhCDNF treatment worsening of restored, p

  7. Slide 7: CDNF Targets Core Pathology Of Parkinson's Disease – Proteostasis

    CDNF Targets Core Pathology Of Parkinson’s Disease – ng the proteome from Parkinson’s disease Proteostasis ing on the power of the natural protein Cerebral Dopamine Neurotrophic Factor roteostasis and slow, regulates • Proteostasis stop, or even reverse proteins neurodegeneration. in body and influe

  8. Slide 8: rhCDNF/xCDNF Act Powerfully On Proteostasis

    MoA & Target Engagement Disease Biomarkers Market Proteostasis Blood Brain Biomarkers Favorable rhCDNF/xCDNF Act Powerfully On Proteostasis target engagement Barrier respond safety profile, validated, penetration significantly to and no proteostasis is high for rhCDNF treatment worsening of restored

  9. Slide 9: CDNF Is Essential For Enteric Dopamine Neuron Development And Survival

    CDNF Is Essential For Enteric Dopamine Neuron Development And Survival • Dopaminergic neurons occur in highest concentration in brain and gut areas of body ○ Role of CDNF can be observed in both brain and gut dopamine neurons • CDNF deficient mice show degeneration of gut dopamine neurons ○ Results

  10. Slide 10: xCDNF (HER096) Convincingly Penetrates Blood Brain Barrier After Simple Skin Injection

    MoA & Target Engagement Disease Biomarkers Market xCDNF (HER096) Convincingly Penetrates Blood Proteostasis target engagement validated, proteostasis restored, potent neuroprotection Blood Brain Barrier penetration is high for xCDNF, highly potent Biomarkers respond significantly to rhCDNF treatment

  11. Slide 11: xCDNF (HER096) Potent Protection Of Dopamine Neurons + Proteostasis

    MoA & Target Engagement Disease Biomarkers Market xCDNF (HER096) Potent Protection Of Dopamine Neurons + Proteostasis target engagement validated, proteostasis restored, potent Blood Brain Barrier penetration is high for xCDNF, highly Biomarkers respond significantly to rhCDNF treatment Favorable sa

  12. Slide 12: xCDNF (HER096) Potent Impact On Key Pathologies Of Parkinsons

    MoA & Target Engagement Disease Biomarkers Market xCDNF (HER096) Potent Impact On Key Pathologies Of Parkinsons Proteostasis Blood Brain Biomarkers Favorable target engagement Barrier respond safety profile, validated, penetration significantly to and no proteostasis is high for rhCDNF treatment wor

  13. Slide 13: HER-096 Has Superior Pharmacological Properties When Compared to Other UPR Modulators

    MoA & Target Engagement Disease Biomarkers Market HER-096 Has Superior Pharmacological Properties When Proteostasis target engagement validated, proteostasis restored, potent neuroprotection Blood Brain Barrier penetration is high for xCDNF, highly potent Biomarkers respond significantly to rhCDNF t

  14. Slide 14: rhCDNF and xCDNF Data Continues To Build

    rhCDNF and xCDNF Data Continues To Build MoA & Target Engagement Disease Biomarkers Market Proteostasis Blood Brain Biomarkers Favorable target engagement Barrier respond safety profile, validated, penetration significantly to and no proteostasis is high for rhCDNF treatment worsening of restored, p

  15. Slide 15: rhCDNF Treatment Effects On Disease Biomarkers In Humans

    rhCDNF Treatment Effects On Disease Biomarkers In Humans • Biomarkers in Cerebrospinal Fluid (CSF) change in response to rhCDNF treatment in some patients • Correlated with improvements in motor function and biological dopamine signals • Some subjects found to carry mutation etiopathologically relat

  16. Slide 16: Data Linking Clinical + Imaging + Biomarker + Genetics Following Treatment With rhCDNF

    Data Linking Clinical + Imaging + Biomarker + Genetics Following Treatment With rhCDNF 3 ○ 60+ year ○ Disease duration: 10 years (from first motor symptoms) ○ 6 months placebo, followed by 6 months rhCDNF 1 2 4 Motor Score Imaging Genotype Patient: Patient: Placebo Placebo —> Mid dose—> Mid dose CDN

  17. Slide 17: A Distinctive Biomarker Signature: Twenty Disease Related CSF Proteins

    A Distinctive Biomarker Signature: Twenty Disease Related CSF Proteins Show Similar Pattern of Change in the “Responders” CHI3L1 6 MO 12 MO 6 MO 12 MO 6 MO 12 MO 6 MO 12 MO 6 MO 12 MO Functional association: Gene Ontology (GO) term enrichment analysis of the 20 CSF proteins 5 S100A8 S100A9 MMP8 MMP9

  18. Slide 18: rhCDNF and xCDNF Data Continues To Build

    rhCDNF and xCDNF Data Continues To Build MoA & Target Engagement Disease Biomarkers Market Proteostasis Blood Brain Biomarkers Favorable target engagement Barrier respond safety profile, validated, penetration significantly to and no proteostasis is high for rhCDNF treatment worsening of restored, p

  19. Slide 19: Parkinson's Disease – Urgent Need For Disease Modifying Treatments

    Parkinson’s Disease – Urgent Need For Disease Modifying Treatments • Exploding incidence of Parkinson’s worldwide … of ‘pandemic proportions’ • Combination of man-made and genetic factors Viewpoint: E.Ray Dorsey. MD, Bastiaan Bloem, MD, PhD 19 1 European Parkinson’s Disease Association www.epda.eu.c

  20. Slide 20: Compelling Commercial Opportunity For Disease Modifying rhCDNF/xCDNF

    Compelling Commercial Opportunity For Disease Modifying rhCDNF/xCDNF Commercial Potential (US and EU5, 2030) $7'000M $6'043M $8’663M $6'000M $5'000M $3'322M $4'000M $3'000M $2'000M $1'265M $294M $2'632M $1'000M $826M $89M $146M $M Parkinson's Disease Stroke Overall, the TAM for Parkinson’s For CDNF/

  21. Slide 21: Timelines & Some Of The Key Planned Milestones

    Timelines & Some Of The Key Planned Milestones Parkinson's Disease and other Commercialization 2H 2021 rhCDNF: Intranasal administration formulation milestones neurodegenerative diseases Approval Phase III (Safety & Efficacy) xCDNF 2H 2021 Parkinson's Disease Pre-clinical efficacy and additional PoC

  22. Slide 22: Conclusion: Why rhCDNF & xCDNF(HER096) Are So Compelling!

    Conclusion: Why rhCDNF & xCDNF(HER096) Are So Compelling! • Powerful validated MoA and scientific merit - Restores proteostasis, needed for neuronal survival, convincingly crosses BBB • Unparalleled biomarker data - Strong impact on markers of disease; clear correlation with clinical & imaging impro

  23. Slide 23: Herantis Pharma Featured in the June 2021 Nature Journal

    Herantis Pharma Featured in the June 2021 Nature Journal Nature Magazine's BioPharma Dealmakers June 2021 edition which focuses on the latest developments in CNS. The Herantis article, titled, Protecting the proteome from Parkinson’s disease, details how Herantis is capitalizing on the power of the

  24. Slide 24: Thank You!

    Thank You! 2 4 24

Herantis Pharma — Investor Presentation (September 2021) on 6ix